hyaluronidase

(redirected from Vitrase)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for hyaluronidase

an enzyme (trade name Hyazyme) that splits hyaluronic acid and so lowers its viscosity and increases the permeability of connective tissue and the absorption of fluids

Related Words

References in periodicals archive ?
2 phase III randomized controlled trials have shown that a single intravireal injection of vitrase is safe and demonstrated efficacy in aiding clearance of vitreous hemorrhage.
The Vitrase 6,200-unit single-dose vial was discontinued, although Vitrase is still available in 200-U/mL vials.
Although the delay is not terribly helpful it has been done for the very best reasons - to ensure that Vitrase has the best possible chance of being successful, " he said.
Three of the groups will each receive one of three different doses of Vitrase (7.
s) Termination of ISTA Vitrase collaboration agreement (including interest income of $0.
7 million (k) Restructuring charge and related inventory write-offs (l) Transition/duplicate operating expenses (m) ISTA Vitrase collaboration fee (n) Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions): Tax effect Non-GAAP pre-tax adjustments of $34.
3 million (h) Transition/duplicate operating expenses (i) ISTA Vitrase collaboration fee (j) Tax effect for non-GAAP adjustments "GAAP" refers to financial information presented in accordance with generally accepted accounting principles in the United States.
1) million (d) Unrealized loss on the mark-to-market adjustment to derivative instruments (e) Income from revised Vitrase collaboration agreement with ISTA pharmaceuticals (f) Total tax effect for non-GAAP pre-tax adjustments and other income tax adjustments, consisting of the following amounts (in millions): Tax effect Non-GAAP pre-tax adjustments of $7.
3 million (d) Interest income related to previously paid state income taxes and reversal of interest expense related to tax settlements (e) Unrealized gain on the mark-to-market adjustment to derivative instruments (f) Termination of ISTA Vitrase collaboration agreement (including interest income of $0.
0 (e) Patent infringement settlement (f) Income tax benefit for previously paid state income taxes and tax effect for non-GAAP adjustments (g) ISTA Vitrase collaboration fee ALLERGAN, INC.
On June 7th, ISTA announced FDA approval of Istalol for glaucoma, which is the company's second FDA approval; the company announced FDA approval for Vitrase as a spreading agent in May.
Vitrase has received "fast-track" designation from the FDA for the treatment of vitreous hemorrhage.